Literature DB >> 19617536

Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.

D S Markovic1, K Vinnakota, S Chirasani, M Synowitz, H Raguet, K Stock, M Sliwa, S Lehmann, R Kälin, N van Rooijen, K Holmbeck, F L Heppner, J Kiwit, V Matyash, S Lehnardt, B Kaminska, R Glass, H Kettenmann.   

Abstract

Diffuse infiltration of glioma cells into normal brain tissue is considered to be a main reason for the unfavorable outcomes of patients with malignant gliomas. Invasion of glioma cells into the brain parenchyma is facilitated by metalloprotease-mediated degradation of the extracellular matrix. Metalloproteases are released as inactive pro-forms and get activated upon cleavage by membrane bound metalloproteases. Here, we show that membrane type 1 metalloprotease (MT1-MMP) is up-regulated in glioma-associated microglia, but not in the glioma cells. Overexpression of MT1-MMP is even lethal for glioma cells. Glioma-released factors trigger the expression and activity of MT1-MMP via microglial toll-like receptors and the p38 MAPK pathway, as deletion of the toll-like receptor adapter protein MyD88 or p38 inhibition prevented MT1-MMP expression and activity in cultured microglial cells. Microglial MT1-MMP in turn activates glioma-derived pro-MMP-2 and promotes glioma expansion, as shown in an ex vivo model using MT1-MMP-deficient brain tissue and a microglia depletion paradigm. Finally, MyD88 deficiency or microglia depletion largely attenuated glioma expansion in 2 independent in vivo models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617536      PMCID: PMC2718387          DOI: 10.1073/pnas.0804273106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Yuzo Kodaira; Jeffrey L Platt
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

2.  Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Jeffrey L Platt
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

3.  In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance.

Authors:  I Guzhova; K Kislyakova; O Moskaliova; I Fridlanskaya; M Tytell; M Cheetham; B Margulis
Journal:  Brain Res       Date:  2001-09-28       Impact factor: 3.252

Review 4.  Molecular mechanisms of glioma invasiveness: the role of proteases.

Authors:  Jasti S Rao
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

5.  Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis.

Authors:  Hidayatullah G Munshi; Yi I Wu; Subhendu Mukhopadhyay; Adam J Ottaviano; Antonella Sassano; Jennifer E Koblinski; Leonidas C Platanias; M Sharon Stack
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

Review 6.  Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP).

Authors:  Pamela Osenkowski; Marta Toth; Rafael Fridman
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

7.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.

Authors:  Rosaria Bassi; Paola Giussani; Viviana Anelli; Thomas Colleoni; Marco Pedrazzi; Mauro Patrone; Paola Viani; Bianca Sparatore; Edon Melloni; Laura Riboni
Journal:  J Neurooncol       Date:  2007-11-02       Impact factor: 4.130

8.  Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells.

Authors:  Iwona Ciechomska; Beata Pyrzynska; Piotr Kazmierczak; Bozena Kaminska
Journal:  Oncogene       Date:  2003-10-23       Impact factor: 9.867

9.  Inhibition of toll-like receptor signaling in primary murine microglia.

Authors:  Rajagopal N Aravalli; Shuxian Hu; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-12-05       Impact factor: 4.147

10.  Immune cell infiltration of intrinsic and metastatic intracranial tumours.

Authors:  Herwig M Strik; Manuel Stoll; Richard Meyermann
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

View more
  158 in total

Review 1.  Microglial cell origin and phenotypes in health and disease.

Authors:  Kaoru Saijo; Christopher K Glass
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

Review 3.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

Review 4.  Targeting specific cells in the brain with nanomedicines for CNS therapies.

Authors:  Fan Zhang; Yi-An Lin; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

Review 5.  Microglial interactions with the neurovascular system in physiology and pathology.

Authors:  Xiaoliang Zhao; Ukpong B Eyo; Madhuvika Murugan; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2018-02-01       Impact factor: 3.964

Review 6.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

7.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

8.  Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

Authors:  Winnie W Pong; Samantha B Higer; Scott M Gianino; Ryan J Emnett; David H Gutmann
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

9.  Immunoexpression of metalloproteinases 2 and 14 and TIMP-2 inhibitor in main types of primary gastric carcinomas and lymph node metastasis.

Authors:  Daniel Cordeiro Gurgel; José Telmo Valença-Junior; Conceição Aparecida Dornelas; Renato Braga Vieira; João Tarcisio Alves Maia-Filho; Roberto Cesar Pereira Lima-Junior; Ronaldo Albuquerque Ribeiro; Paulo Roberto Carvalho Almeida
Journal:  Pathol Oncol Res       Date:  2014-05-07       Impact factor: 3.201

10.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.